Skip to content
Medical Health Aged Care

Huntington’s disease families may benefit from a high-fibre diet

The Florey 2 mins read
Dr Carolina Gubert and Professor Anthony Hannan.

In a groundbreaking study, Florey researchers have shown for the first time that high-fibre intake has a positive effect on Huntington’s disease. 

The Florey’s Professor Anthony Hannan, Head of the Epigenetics and Neural Plasticity Group, and Research Co-Lead for the Mental Health Mission, said the results of a study published in Brain Behavior and Immunity indicate that dietary fibre could delay the onset of Huntington’s symptoms. 

There is currently no cure or effective treatment for this devastating disease, which can strike in the prime of life and is always fatal. 

“Huntington’s disease is a debilitating inherited progressive neurodegenerative disorder caused by a faulty gene,” said Professor Hannan, the paper’s senior author. 

“Patients experience worsening motor, cognitive and psychiatric symptoms over many years. The disease also causes gastrointestinal symptoms and in recent years we have discovered disruption to the composition of bacterial populations within the gut.” 

Professor Hannan, Dr Carolina Gubert and their team set out to discover whether dietary interventions could reduce Huntington’s symptoms. 

“Working with a preclinical model, we tested the impact of high, medium and zero levels of dietary fibre consumption. What we found is very exciting. For the first time we’ve shown that high-fibre intake not only enhanced gastrointestinal function, it also improved cognition and behaviour.” 

The study’s lead author, Florey Research Fellow Dr Carolina Gubert, said the study showed that dietary fibre can beneficially modulate Huntington’s disease, and this could occur through the microbiome-gut-brain axis. 

“The gut microbiome in our mouse model of Huntington’s, carrying the human disease gene mutation, responded differently to the high fibre intake compared to the non-Huntington’s mice. This is consistent with our previous discovery that the gut microbiome is altered in Huntington’s disease.” 

Professor Hannan said the results could also have implications for other brain disorders exhibiting dysfunction of the gut-brain axis, such as depression and dementia, and further research will establish if this is the case. 

The Australian Dietary Guidelines are an excellent evidence-based guide for food intake for optimal health, he said.  

The Florey team is now planning to work with Australian and international colleagues to establish a clinical trial to test whether such a high-fibre diet is beneficial in humans.  


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere. 

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley

Manager | Media and Communications

kathryn.powley@florey.edu.au

0456 666 271

 

Media

More from this category

  • Medical Health Aged Care
  • 27/02/2024
  • 23:07
Monopar Therapeutics Inc.

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients. Professor Hicks will enroll patients at the Melbourne Theranostic Innovation Centre (MTIC) and will use one of the world's most sensitive clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the targeting ability of MNPR-101-Zr in cancer patients.“We are very excited…

  • Indigenous, Medical Health Aged Care
  • 27/02/2024
  • 14:26
Institute for Urban Indigenous Health

Reduction in Indigenous newborn removals by child protection services

Australian research published this month shows women who received care through an innovative Indigenous-led model of maternity care were three times less likely to have their Indigenous newborn removed by child protection services than women who received standard maternity care. The research lands at the same time as the Australian Government’s Closing the Gap 2023 Annual Report which shows the rate of over-representation of Indigenous children in out-of-home care in Australia continues to increase. Kristie Watego, Birthing in Our Community (BiOC) Service Development Manager, Institute for Urban Indigenous Health (IUIH), said the results show it is possible to significantly reduce…

  • Medical Health Aged Care
  • 27/02/2024
  • 09:31
Dementia Australia

Come walk or jog with us in Perth. We are in this together!

The 2024 Perth Memory Walk & Jog is nearly here with the event taking place on Sunday 17 March at Burswood Park, Burswood. Dementia Australia’s largest fundraising event hopes to attract thousands of people across Australia to help raise more than $2 million in support of people living with dementia. Funds raised at our upcoming event in Perth will help advance the work of Dementia Australia which delivers invaluable support, education and resources for people living with dementia, their families and carers. Memory Walk & Jog is about being part of the community and feeling supported. We are in this…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.